

Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of *R*- and *S*-equols and their differing binding and biological activity through estrogen receptors alpha and beta

Rajeev S. Muthyala,^a Young H. Ju,^b Shubin Sheng,^c Lee D. Williams,^d
Daniel R. Doerge,^d Benita S. Katzenellenbogen,^c William G. Helferich^{b,*}
and John A. Katzenellenbogen^{a,*}

^aDepartment of Chemistry, University of Illinois, 600 South Mathews Avenue, Urbana, IL 61801, USA

^cDepartment of Molecular and Integrative Physiology, University of Illinois, Urbana, IL 61801, USA

^bDepartment of Food Science and Human Nutrition, University of Illinois, 905 South Goodwin Avenue, Urbana, IL 61801, USA

^dNational Center for Toxicological Research, Jefferson, AR 72079, USA

Received 28 July 2003; accepted 19 November 2003

Abstract—Equol is a metabolite produced in vivo from the soy phytoestrogen daidzein by the action of gut microflora. It is known to be estrogenic, so human exposure to equol could have significant biological effects. Equol is a chiral molecule that can exist as the enantiomers *R*-equol and *S*-equol. To study the biological activity of racemic ($\pm$)-equol, as well as that of its pure enantiomers, we developed an efficient and convenient method to prepare ($\pm$)-equol from available isoflavanoid precursors. Furthermore, we optimized a method to separate the enantiomers of equol by chiral HPLC, and we studied for the first time, the activities of the enantiomers on the two estrogen receptors, ER α and ER β . In binding assays, *S*-equol has a high binding affinity, preferential for ER β (K_i [ER β] = 16 nM; β/α = 13 fold), that is comparable to that of genistein (K_i [ER β] = 6.7 nM; β/α = 16), whereas *R*-equol binds more weakly and with a preference for ER α (K_i [ER α] = 50 nM; β/α = 0.29). All equol isomers have higher affinity for both ERs than does the biosynthetic precursor daidzein. The availability and the in vitro characterization of the equol enantiomers should enable their biological effects to be studied in detail.

© 2004 Elsevier Ltd. All rights reserved.

1. Introduction

Isoflavanoids found in soy, such as genistein and daidzein, have attracted great interest as dietary phytoestrogens that might be effective for menopausal hormone replacement therapy.¹ Suggestions have been made that these isoflavones might also be useful in the prevention or treatment of breast cancer.² Recent studies in animals, however, raise the possibility that the mammary cell growth-promoting effects of these compounds might, in fact, increase breast cancer risk and might also compromise the effectiveness of breast cancer hormone


therapy using antiestrogens such as tamoxifen.³ Thus, it is unclear whether the biological effect of these phytoestrogens will be a health benefit or a risk to humans. It is also possible that their potential for benefit to one tissue or one health condition could be compromised by their potential risk to another tissue or condition.

In examining the impact of the estrogenic activity of soy phytoestrogens, one needs to consider not only the isoflavones and their conjugates that are ingested, but also biologically active metabolites that might be generated from them in vivo. Daidzein, a prominent isoflavone in soy, is converted to the corresponding chroman, *S*-(–)-equol, a compound whose estrogenic activity exceeds that of daidzein.^{4,5} This reductive metabolic conversion appears to result from the action of gut microflora.⁶ Equol was first isolated from pregnant mares' urine in 1932⁷ and was subsequently identified in the plasma of sheep (presumably derived from formononetin in red

Abbreviations: ER, Estrogen Receptor; HPLC, High Performance Liquid Chromatography; RBA, Relative Binding Affinity; HEC-1, Human Endometrial Carcinoma Cells-1.

* Corresponding authors. Tel.: +1-217-333-6310; fax: +1-217-333-7325 (W.H.); tel.: +1-217-244-5414 (J.A.K.); e-mail addresses: helferich@staff.uiuc.edu; jkatzene@uiuc.edu

clover)⁸ and in human urine (from daidzein).⁹ Curiously, the extent of conversion of isoflavones to equol varies greatly among humans, presumably because of differences in the composition of gut microflora. Although typical laboratory animal species (mouse, rat, monkey) consistently produce high levels of equol, only about 35% of humans are high equol producers, and variations in urinary equol levels as great as 600-fold have been noted.^{10–13}



Equol is a chiral molecule that can exist in two enantiomeric forms, and the enantiomer produced by metabolic reduction from isoflavones is known to be *S*-(-)-equol. Equol is uterotrophic in mice, having a potency similar to that of genistein, and its binding affinity for the estrogen receptor from sheep uterus is reported to be about 1/250th that of estradiol.¹⁴ ($\pm$)-Equol produced by synthesis has been shown to induce breast cancer cell proliferation in culture at concentrations as low as 100 nM.¹⁵

As part of an effort aimed at investigating the role that equol might play in breast cancer and the potential for differential activity of the two equol enantiomers through the two estrogen receptors, ER α and ER β ,¹⁶ we encountered the need to prepare equol on a large scale and to obtain pure samples of *S*- and *R*-equol. In this report, we describe a convenient preparation of ($\pm$)-equol based on transfer hydrogenation that begins from readily available isoflavone precursors, as well as a biomimetic synthesis of ($\pm$)-equol. We also effect a robust chromatographic resolution of ($\pm$)-equol into *R*- and *S*-equol. We then evaluate, for the first time, the ER α and ER β binding affinity and transcriptional activity of ($\pm$)-, *R*- and *S*-equol, and compare them with those of the biosynthetic precursor daidzein and the other abundant soy isoflavone genistein. Curiously, the equol enantiomers show differential behavior on the two ER subtypes, with *S*-equol having a preference for ER β and *R*-equol having a preference for ER α .

2. Results

2.1. Synthesis


Our starting materials for the production of equol were the isoflavonoids formononetin and daidzein, which are readily available in large quantities from red clover and soy, respectively. The key step in the conversion of isoflavonoids to equol involves reduction of a vinylogous ester to an ether functional group. Most examples of such reductions involve either multiple steps or toxic reagents, with the exception of two reports,^{17,18} both of which utilized hydrogenation in acetic acid with 10%

palladium on carbon as catalyst. There are two major disadvantages with these particular procedures, however: first, the catalyst had to be activated prior to use by stirring under oxygen for 3 days and second, large amounts of catalyst were used. For example, 30 g of 10% palladium on carbon was used to reduce 6.7 g of daidzein diacetate. Given the cost of the palladium catalyst (\$60 for 10 g), it is clear that scaling up the reduction to give, for example, 100 g of equol would be prohibitive.

Transfer hydrogenation is an attractive alternative to conventional hydrogenation, and a popular reagent for this reaction is ammonium formate.¹⁹ Ram and Spicer noted that ketones and aldehydes undergo reduction to methylene groups using ammonium formate, provided that acetic acid is used as the solvent.²⁰ To test whether this methodology could be extended to the vinylogous ester carbonyl functionality of isoflavones, we performed exploratory experiments. Using formononetin in a model reaction, we found that with ammonium formate in acetic acid solvent and 10% palladium on carbon as the catalyst, we obtained monomethyl equol in 11% yield. The rest of the material consisted of products arising from partial reduction of either the double bond or the keto group. Longer reaction times did not lead to any improvement in yield. In further investigations in alternative solvents, such as tetrahydrofuran or ethanol, we observed only partial reduction of the double bond of isoflavonoids, as noted in the literature.²¹ Attempts to use alternative transfer hydrogenation sources such as cyclohexene were also not successful. By varying the catalyst, we found that Raney Ni also led only to a mixture of partially reduced products. We were gratified to find, however, that Pearlman's catalyst,²² which is 20% Pd(OH)₂ on carbon, was highly effective in this reduction.

Using this catalyst, we could reduce formononetin to monomethyl equol in 68% yield (Scheme 1). The methyl protecting group of the latter compound could be subsequently removed using aluminum trichloride in the presence of ethane thiol²³ to give equol in 84% yield. The overall yield for this two-step process is 57%. It is more convenient, however, to prepare equol directly from daidzein, and this direct reduction can be done in 61% yield (Scheme 1). We have used the latter one-step process to obtain > 100 g of ($\pm$)-equol from daidzein.

In addition to methods involving hydrogenation, we also examined the possibility of using reagents such as NaBH₄/CH₃CO₂H or Et₃SiH/CF₃CO₂H to reduce formononetin or its protected derivatives. But all such attempts led only to complete recovery of the starting material. Since these reagents are known not to reduce ester groups, the negative results presumably indicate that the carbonyl group of formononetin behaves more like an ester carbonyl rather than a ketone functionality. Thus, we anticipated that more reactive hydride donors, such as those derived from dihydroaromatics, could be used to accomplish the reduction. A good example of this class of hydride donors is dihydroacridine, a compound that has, in fact, been reported to reduce



Scheme 1.


xanthenes, which bear structural and functional similarities to isoflavones.²⁴ In our attempts to extend this reaction to isoflavones, we found that using trifluoroacetic acid as the solvent and dihydroacridine²⁵ as the reductant, formononetin could indeed be converted to monomethyl equol (Scheme 2), in moderate yield.

We believe that the above conversion is 'biomimetic' in nature, since dihydroacridine closely mimics the function of NADH, which is the most likely reducing agent in a biosynthetic context. An interesting sidelight of this reaction is that its progress can be followed by the increase in intense fluorescence of acridine as it is being generated.

2.2. Chromatographic resolution of *R*- and *S*-equol and stereochemical assignment

Equol isomers were initially separated using an analytical scale (2 mm diameter) β -cyclodextrin stationary phase liquid chromatography (LC) column under reversed phase conditions. Figure 1 shows the excellent separation of the two enantiomeric forms of racemic equol under these analytical scale conditions. The separation was then scaled up to a 10 mm diameter LC column to effect a semi-preparative isolation of approximately 10 mg total from each peak; good separations were obtained with injection of up to 400 μg of the racemate.

The individual collected fractions were analyzed using HPLC with electrospray mass spectrometric (ES–MS/MS) detection in the product ion mode (m/z 80–250 from m/z 243), and the mass spectra of the individual enantiomers were identical to that observed for racemic equol (product ions m/z 133, 123, 107, 105; data not shown). The purified fractions contained <0.3% of the other isomer, based on LC-ES/MS/MS analysis; furthermore, no other chemical contaminants were observed in either fraction by using LC-UV or LC-ES/MS/MS analysis.



Scheme 2.

The CD spectra obtained from the isolated peaks are shown in Figure 2. Peak 1 (17.5 min retention time) showed negative ellipticity at 280 nm, whereas Peak 2 (19.4 min retention time) showed positive ellipticity, with the two CD spectra being essentially mirror images of one another, properties that are characteristic of an enantiomeric pair. Based on prior structural assignment of (–)-equol as *S*-equol (Beilstein registry number 87752), Peak 1 in Figure 1 is *S*(–)-equol and Peak 2 is *R*(+)-equol. As noted above, *S*(–)-equol is the naturally occurring enantiomer.^{26,27}

2.3. Estrogen receptor binding affinity of *R*- and *S*-equol and the related soy isoflavones, daidzein and genistein

The binding affinities of (±)-, *R*- and *S*-equols to ER α and ER β are shown in the first two sections of Table 1 (RBA values and K_i values), together with those of daidzein and genistein for comparison. Binding affinities were determined by a competitive radiometric binding assay using purified full length human ER α and ER β , with [^3H]estradiol as tracer. In this assay, the affinities are obtained as Relative Binding Affinity (RBA) values, where estradiol has an affinity of 100.

While RBA values can be used to make comparisons between the binding affinities of different compounds on the *same* ER subtype, they are not appropriate for comparisons between *different* subtypes (e.g., ER α and ER β), because estradiol (the reference compound and tracer in the competitive binding assays) binds to ER α with an affinity ca. 2.5 times higher than to ER β ($K_d=0.2$ nM for ER α versus $K_d=0.5$ nM for ER β).²⁸ Therefore, for each compound on each ER subtype, we have calculated the corresponding equilibrium binding inhibition constant or K_i values. The K_i values of the compounds represent their absolute affinities for both ER subtypes, and they are also the appropriate indices for comparison with the potencies of these compound (EC_{50} values) determined in the transcription assays (see below).

The equol enantiomers have distinctly different binding affinities: The absolute binding affinities (K_i values) of the naturally occurring equol enantiomer (*S*-equol) and of the unnatural enantiomer (*R*-equol) on ER α and ER β are nearly reversed from one another, with *S*-equol having a strong preference for ER β ($\beta/\alpha=13$) and




Figure 1. Separation of equol enantiomers by chiral phase liquid chromatography. Separations were done on an analytical column with a β -cyclodextrin-based chiral stationary phase, under reversed phase conditions (see Experimental Methods). *Panel A.* Chromatogram of equol racemate. *Panel B.* Chromatogram of *S*-(-)-equol obtained by preparative chiral LC. *Panel C.* Chromatogram of *R*-(+)-equol obtained by preparative chiral LC.




Figure 2. Circular dichroism spectra of equol enantiomers. The curve showing the negative ellipticity is from material in the first peak to elute (corresponding to *S*-(-)-equol, see Fig. 1A), and the curve showing the positive ellipticity is from material in the second peak to elute (corresponding to *R*-(+)-equol, see Fig. 1A). For details, see Experimental Methods.

R-equol having a moderate preference for ER α ($\beta/\alpha = 0.29$). Significantly, the binding characteristics of *S*-equol, particularly its high ER β preference, are most comparable to those of the most estrogenic soy isoflavone genistein, although *R*-equol binds better to ER α than does genistein. Also of note is the fact that all of the equols have much higher affinities for both ERs than does the abundant soy isoflavone daidzein, the biosynthetic precursor. As expected, the binding affinity of the racemate, ($\pm$)-equol, is almost exactly the average of that of the individual equol enantiomers. The much higher binding affinity of genistein relative to daidzein on ER β is likely due to the decrease in polarity of the vinylogous ester functionality that occurs as a result of the intramolecular hydrogen bond between the carbonyl group and the proximal -OH function in genistein, an interaction that is absent in daidzein.²⁹

2.4. Transcriptional activities of the equols and isoflavone compounds

The equols and the related isoflavones were assayed for transcriptional activity through both estrogen receptor subtypes. These cotransfection assays were conducted in

human endometrial carcinoma (HEC-1) cells, using expression plasmids for either full-length human ER α or ER β and an estrogen-responsive luciferase reporter gene.³⁰ In all cases, transcriptional activity of the various compounds through either ER α or ER β is presented relative to that obtained with 10^{−9} M estradiol, which is set at 100%. The dose–response curves are

shown in Figure 3, and the EC₅₀ values (which are comparable to the K_i values for binding affinity, not the RBA values) are summarized in the rightmost portion of Table 1.

From the transcription activation curves, it is apparent that all of the compounds are agonists on both ER α and

Table 1. Binding affinities^{a,b} and Transcriptional potencies^c of isoflavones and equol for ER α and ER β

Ligand	RBA ^a (%)		β/α^d	K _i ^b (nM)		β/α^d	EC ₅₀ ^c (nM)		β/α^d
	hER α	hER β		hER α	hER β		hER α	hER β	
Estradiol	100	100	1	0.2	0.5	0.4	0.021	0.11	0.19
Daidzein	0.010±0.006	0.040±0.001	4	2000	1300	1.5	250	100	2.5
Genistein	0.017±0.003	7.4±0.5	440	1200	6.7	180	80	6.6	12
(±)Equol	0.20±0.02	1.60±0.04	8	100	31	3.2	200	74	2.7
R(+)Equol	0.40±0.04	0.30±0.02	0.7	50	170	0.29	66	330	0.20
S(−)Equol	0.10±0.01	3.20±0.06	32	200	16	13	85	65	1.3

^a RBA = Relative Binding Affinity (as a%) measured in a competitive binding assay (see Experimental). The K_d values of estradiol for ER α and ER β are 0.2 nM and 0.5 nM, respectively.²⁸

^b K_i = equilibrium binding competition constant, calculated from the K_d of estradiol on ER α or ER β : (K_d/RBA)×100.

^c Transcriptional activity measured using a cotransfection assay in HEC-1 cells (see Experimental and Fig. 3). Transcriptional potency = EC₅₀.

^d For each index, the β/α ratio is calculated such that the ratio is > 1 for compounds having higher affinity or greater potency on ER β than on ER α .




Figure 3. Dose–response curve for transcriptional activation by the indicated compounds. In each case, the solid circles are for ER α and the solid triangles are for ER β . (A) estradiol (E₂); (B) genistein; (C) daidzein; (D) (±)-equol; (E) S-equol; (F) R-equol. Human endometrial carcinoma (HEC-1) cells were transfected with expression vectors for ER α or ER β and an (ERE)₂-pS2-luc reporter gene and were treated with estradiol or the specified compound for 24 h, at the concentrations indicated. Luciferase activity was expressed relative to β -galactosidase activity from an internal control plasmid. The maximal activity with 1 nM estradiol was set at 100% (A). Values are the mean±SD from three separate experiments.

ER β , giving maximal efficacies that are comparable to that of estradiol. Genistein appears to be somewhat of a superagonist on ER α , a characteristic that has been noted by others,³¹ and the maximum efficacy of *R*-equol might be slightly less than that of estradiol.

When the potencies are compared, it is evident that all of the compounds are less potent than estradiol. Overall, the potencies (EC₅₀ values) of the equols and the two isoflavones are comparable (ca. within a factor of 10) to their binding affinities (K_i values); the same is true for their ER α versus ER β potencies (β/α values). The only significant difference between affinity and potency is that *S*-equol has a high binding affinity preference for ER β ($\beta/\alpha=13$), but essentially no ER subtype preference in terms of transcriptional potency ($\beta/\alpha=1.3$). This is in contrast to the ER α preference of *R*-equol and the ER β preference of genistein, evident in their binding affinities ($\beta/\alpha=0.29$ and 180, respectively), that are largely maintained in their transcriptional potencies ($\beta/\alpha=0.20$ and 12, respectively).

3. Discussion

Legumes (including soy, sprouts, and red clover) are rich sources of isoflavones that have been shown to be cancer-preventive.^{32,33} The major isoflavones found in soybeans and soy products are genistin and daidzin (β -glycosides), and their aglycone forms, genistein and daidzein. Biochanin A and formononetin are proestrogenic isoflavones also found in legumes.³⁴ After ingestion, the β -glycosides undergo further metabolism by intestinal microflora,^{35,36} and through the action of bacterial glucosidases, they are converted to aglycones (genistein and daidzein).^{37–39} In humans, 30–40% of the population can convert daidzein to equol.^{40,41} The amount of urinary equol excretion is correlated with the consumption of soy products^{10,42} and a reduced risk of breast cancer.^{43,44} In vitro experiments suggest that equol might be more estrogenic than daidzein.^{4,35,41} The actions of estrogens, including those of the phytoestrogens such as daidzein (and its equol metabolite) and genistein, the principal phytoestrogens in soy, are mediated through the estrogen receptors (ERs), of which there are two subtypes, ER α and ER β .¹⁶ These proteins are ligand-regulated transcription factors, and their tissue distribution, biological functions, and response to structurally diverse ligands are quite different.^{16,45–49} The phytoestrogens are often considered to be ER β -selective ligands.^{31,50} Equol is a chiral molecule, capable of existing in two enantiomeric forms with potentially different biological activities, with natural equol, being the *S*(–) enantiomer.^{7,26,27} The relative binding affinity and transcriptional potency of the equol enantiomers for the two ER subtypes have not been reported previously.

To facilitate studies on the receptor interactions and estrogenic activity of equol and its enantiomers, as well as experiments in animal models of human diseases, we have developed, as reported here, a convenient method to prepare ($\pm$)-equol in multigram quantities from

commercially available isoflavone precursors. It is not, however, an enantioselective synthesis, although enantioselective syntheses have been described for both optical antipodes of equol dimethyl ether starting from substituted phenylacetic acids, using a stereoselective alkylation and cyclization strategy.⁵¹ Rather than attempt to replicate this multistep procedure, we chose simply to resolve *R*- and *S*-equol by chiral LC. Using a chiral β -cyclodextrin column, we obtained an excellent separation that could be scaled up readily to produce multi-milligram amounts of the pure equol stereoisomers. The identity of the eluted material was confirmed by LC-ES/MS/MS, and the assignment of stereoisomers was done by CD; the first eluting peak gave a CD spectrum having a long-wavelength peak with a negative ellipticity, which is known to correspond to *S*-equol, the naturally occurring enantiomer, and the second peak, with a positive CD corresponding to *R*-equol.^{26,27}

The two equol enantiomers showed very different behavior in terms of their binding affinities and transcriptional potencies with ER α and ER β . In competitive binding affinity assays, we found that the binding affinity of the natural enantiomer, *S*-equol, is quite high and shows a 13-fold preference for ER β , being similar in these respects to genistein ($\beta/\alpha=180$), the most estrogenic soy isoflavone, whereas *R*-equol shows a preference for ER α ($\beta/\alpha=0.29$). Daidzein, the isoflavone precursor of equol, binds more weakly and shows little ER subtype selectivity. In cotransfection transcription assays, the potency of the equol stereoisomers and of genistein nicely reflect their binding affinities for ER α and ER β , although the strong ER β preference of *S*-equol in terms of binding affinity is considerably muted and the transcriptional potency of daidzein is higher than expected from its affinity. Thus, genistein is the only compound that stands out as having an accentuated potency for ER β in transcription assays, whereas both *S*-equol and genistein have a preference for ER β in terms of binding. Whether these differences in ER subtype selectivity between binding and transcription assays are due to cellular metabolism or differential interaction with cellular coregulators is an issue that needs to be evaluated further.^{52–55}

It is of note that the range of ER α binding affinity values reported for soy phytoestrogens is remarkably wide, with values for genistein spanning nearly a 100-fold range (RBA values 0.010–0.88) and for daidzein an 8-fold range (RBA values 0.01–0.08).⁵⁶ The ER α binding affinity values we have obtained for both of these compounds (Table 1) are clearly within these ranges, but we note that it proved far more difficult to obtain consistent binding affinity values for these two compounds than for a very wide range of other estrogens that we have evaluated in the same binding assay over a period of more than 30 years. Furthermore, in our hands genistein has a higher binding affinity for the ER in a preparation from lamb uterus, giving an RBA value of 0.69, a value that is similar to that obtained in rat uterine ER by Sheehan (RBA 0.45).⁵⁷ One would expect the ER from these uterine sources to be predominantly ER α .^{16,58}

The different tissue distribution and distinct biological roles of ER α and ER β and their potential for mediating divergent effects of estrogens on target tissue stimulation and proliferation highlight the importance of characterizing carefully the efficacy and potency of various estrogens through these two receptors. ER α is found in most estrogen target tissues, in some cases nearly by itself or accompanied by lower levels of ER β . ER β , on the other hand, is found by itself or in higher levels than ER α only in a few regions of the brain, in the ovary, prostate and testis.^{16,58,59}

Although at this point not fully understood, the biological functions of ER α and ER β have been studied both by the generation of gene knockout mice^{60,61} and by the use of ER subtype-selective ligands.⁶² One interesting hypothesis that has been advanced, which is consistent with the generally greater transcriptional effectiveness of ER α vs ER β , is that estrogens acting through ER α effect a strong stimulatory or proliferative drive in target tissues (or estrogen-responsive tumors) and that estrogens acting through ER β moderate this drive.⁶³ Thus, both the relative levels of ER α and ER β , as well as the potency or efficacy selectivity of the particular estrogen that is acting through these two subtypes, could determine the ultimate magnitude of the stimulatory effect. Consistent with this hypothesis are the reports that as breast and prostate tumors become progressively more malignant, there is a general increase in the ratio of ER α to ER β ,^{63–65} as well as the reports of hyperplasia in certain target tissues in ER β knockout mice,⁶³ although the observations of all laboratories are not consistent on this latter issue.⁶⁶ In light of our study on the effects of equol and its enantiomers on the two estrogen receptor subtypes, it would appear prudent to evaluate carefully, *in vivo*, the biological effects of not only the isoflavones but also their metabolites and their stereoisomers. Such investigations would greatly help in evaluating the potential effects of the ingestion of soy isoflavones on human health and disease.

4. Conclusion

We have developed a simple synthetic route to equol from readily available isoflavanoid starting materials. Chiral HPLC provided ready access to the two enantiomers of equol and allowed us to examine, for the first time, their differential effects on the two estrogen receptor subtypes. S-equol shows a strong binding preference in favor of ER β that is greater than that of its daidzein precursor and comparable to that of genistein, whereas the R isomer exhibits a binding selectivity for ER α . *In vitro* transfection assays show that the S isomer, however, has little ER β selectivity in terms of transcriptional potency.

5. Experimental

5.1. Materials

Formononetin was a gift from Dr. Muralee Nair, Michigan State University, East Lansing, MI). Daidzein

was purchased from Indofine Chemical (Belle Mead, NJ). Ammonium formate, ethanethiol and 20% Pd(OH)₂ on carbon were purchased from Aldrich Chemical Company.

5.2. Chemical synthesis, separation and spectroscopic methods

5.2.1. Reduction of formononetin. Formononetin (5.0 g, 18.6 mmol) was suspended in acetic acid (25 mL) together with ammonium formate (11.75 g, 186 mmol) and 20% Pd(OH)₂ on carbon (4.8 g). The reaction mixture was then refluxed for 1 h and allowed to cool to room temperature. After diluting with 50 mL of EtOAc, the reaction mixture was filtered through a 2 cm pad of Celite that was subsequently washed with an additional 150 mL of EtOAc. The filtrate was evaporated in vacuo to give a light brown oily residue which was purified on silica gel using 15% EtOAc/hexane as the solvent. Trituration of this oil with 125 mL of water gave a white fluffy solid that was filtered and dried to give 3.2 g (68%) of monomethyl equol. ¹H NMR (500 MHz, acetone-*d*₆): δ 7.05 (d, 8.4 Hz, 2H), 6.84 (d, 8.1 Hz, 1H), 6.74 (d, 8.4 Hz, 2H), 6.30 (dd, 2.36 Hz, 8.1 Hz, 1H), 6.23 (d, 2.36 Hz, 1H), 4.15 (m, 1H), 3.87 (t, 10.72 Hz, 1H), 3.67 (s, 3H), 3.00 (m, 1H), 2.81 (m, 2H). Mp 156–158 °C; reported:⁶⁷ 158 °C.

5.2.2. Synthesis of (±)-equol from monomethyl equol.

Aluminum trichloride (2.10 g, 15.7 mmol) was mixed with ethane thiol (12 mL) together with 5 mL of anhydrous CH₂Cl₂ at 0 °C under nitrogen. The light yellow solution was allowed to stir for 5 min. after which monomethyl equol (1.0 g, 3.9 mmol) was added in one portion. After stirring for 1 h at 0 °C, the reaction was quenched by addition of water and the mixture was warmed to 40 °C and left to stir at that temperature, with the flask open to air, until all traces of ethane thiol were completely removed. A white solid which precipitated out was dissolved in EtOAc (20 mL), washed with 10% HCl and dried on MgSO₄. The organic solvent was removed in vacuo to give a light brown oil which was chromatographed on silica gel using 35% EtOAc/hexane as the eluent to give 0.78g (84%) of (±)-equol. ¹H NMR (500 MHz, acetone-*d*₆): δ 6.93 (d, 8.58 Hz, 2H), 6.75 (d, 8.15 Hz, 1H), 6.69 (d, 8.58 Hz, 2H), 6.27 (dd, 2.36 Hz, 8.15 Hz, 1H), 6.22(d, 2.36 Hz, 1H), 4.11 (m, 1H), 3.79 (t, 10.72 Hz, 1H), 2.97 (m, 1H), 2.75 (m, 2H). ¹³C NMR (125 MHz, acetone-*d*₆): δ 155.8, 154.5, 132.1, 129.8, 127.9, 115.2, 113.1, 107.8, 102.7, 70.7, 37.5, 31.5. Mp 184–187 °C; reported⁷ 187–189 °C.

5.2.3. Conversion of daidzein to (±)-equol.

Daidzein (5.0 g, 18.6 mmol) was suspended in acetic acid (25 mL) together with ammonium formate (11.75 g, 186 mmol) and 20% Pd(OH)₂ on carbon (4.8 g). The reaction mixture was then refluxed for 1 h and allowed to cool to room temperature. After diluting with 50 mL of EtOAc, the reaction mixture was filtered through a 2 cm pad of Celite that was subsequently washed with an additional 150 mL of EtOAc. The filtrate was evaporated in vacuo to give a light brown oily residue that was purified on silica gel using 30% EtOAc/hexane as the solvent. Trituration of this oil with 125 mL of water gave a white

fluffy solid which was filtered and dried to give 2.9 g (61%) of ($\pm$)-equol. ^1H NMR (500 MHz, acetone- d_6): δ 6.93 (d, 8.58 Hz, 2H), 6.75 (d, 8.15 Hz, 1H), 6.69 (d, 8.58 Hz, 2H), 6.27 (dd, 2.36 Hz, 8.15 Hz, 1H), 6.22 (d, 2.36 Hz, 1H), 4.11 (m, 1H), 3.79 (t, 10.72 Hz, 1H), 2.97 (m, 1H), 2.75 (m, 2H). ^{13}C NMR (125 MHz, acetone- d_6): δ 155.8, 154.5, 132.1, 129.8, 127.9, 115.2, 113.1, 107.8, 102.7, 70.7, 37.5, 31.5. Mp 184–187°C; reported:⁷ 187–189°C.

5.2.4. Resolution of equol enantiomers by chiral liquid chromatography (LC). Initial LC separation was performed using an HP1050 quaternary pumping system (Hewlett Packard, Palo Alto, CA) and a Dionex AS3500 autosampler (Dionex, Sunnyvale, CA) attached to a PC1000 data handling system (Thermo Separation Products, San Jose, CA). UV detection was provided by a Spectraphysics MWD (Thermo Separation Products, San Jose, CA) at a wavelength of 280 nm. Enantiomeric separation was achieved using a Cyclobond I 2000 RSP β -cyclodextrin-R,S-hydroxypropyl ether chiral stationary phase (analytical column 250 $\times$ 2.0 mm, 5 μm particle size; semi-preparative column 250 $\times$ 10 mm, 5 μm , particle size, Astec, NJ, USA) and an isocratic mobile phase consisting of 65% 0.1% formic acid (aq) and 35% of acetonitrile. Respective flow rates for the analytical and semi-preparative columns were 0.25 and 5 mL/min. Injection volumes ranged from 5–100 μL , and all separations were performed at ambient temperature.

5.2.5. Mass spectrometry. LC with tandem mass spectrometry (LC-MS/MS) was conducted using a Waters 2790 liquid handling system (Waters Assoc., Milford, MA) and a Quattro Ultima triple quadrupole mass spectrometer equipped with an electrospray (ES) interface (Micromass, Manchester, UK). The entire column effluent (0.25 mL/min) was directed into the ion source held at 120°C for acquisition of positive ions in the product ion or multiple reaction monitoring modes (MRM), as previously described.⁶⁸

5.2.6. Circular dichroism (CD) spectrophotometry. CD spectra of separated equol enantiomers were obtained at ambient temperature by using a Jasco 500A spectropolarimeter equipped with a quartz cell (1 cm path length) containing equol solutions in 50% aqueous methanol that produced 1 AU in a spectrophotometer. The spectropolarimeter was calibrated using (*1S*)-(+)-10-camphorsulfonic acid before use.

5.3. Estrogen receptor binding assays

Relative binding affinities were determined by competitive radiometric binding assays using 10 nM [^3H]E₂ as tracer, using methods previously described.^{28,49,69} The source of ER was purified full-length human ER α and ER β purchased from Pan Vera (Madison, WI).^{28,49,69} Incubations were done at 0°C for 18–24 h, and hydroxylapatite was used to absorb the purified receptor-ligand complexes (human ERs).^{28,49,69} The binding affinities are expressed as relative binding affinity (RBA) values, where the RBA of estradiol is 100%; under these

conditions, the K_d of estradiol for ER α is ca. 0.2 nM, and for ER β 0.5 nM.²⁸ The determination of these RBA values is reproducible in separate experiments with a CV of 0.3, and the values shown represent the average $\pm$ range or SD of 2 or more separate determinations, respectively.

5.4. Cell culture and transcription activation assays

Human endometrial carcinoma (HEC-1) cells were maintained in culture as described.³⁰ Transfection of HEC-1 cells in 24-well plates used a mixture of 0.35 mL of serum-free Improved Minimal Essential medium (IMEM) and 0.15 mL of Hank's Balanced Salt Solution (HBSS) containing 5 μL of lipofectin (Life Technologies, Rockville, MD), 1.6 μg of transferrin (Sigma, St. Louis, MO), 0.5 μg of pCMV β -galactosidase as internal control, 1 μg of the reporter gene plasmid, 100 ng of ER expression vector, and carrier DNA to a total of 3 μg DNA per well. The cells were incubated at 37°C in a 5% CO₂ containing incubator for 6 h. The medium was then replaced with fresh medium containing 5% charcoal-dextran treated calf serum and the desired concentrations of ligands. Reporter gene activity was assayed at 24 h after ligand addition. Luciferase activity, normalized for the internal control β -galactosidase activity, was assayed as described.³⁰

Acknowledgements

This work was supported by National Institutes of Health grants: PHS 5R37 DK15556 (to J. A. K.), 5R01 CA19118 (to B. S. K.), and 5R01 CA77355 (to W. G. H.), and by a grant from the Breast Cancer Research Foundation (to B. S. K.). We thank Kathryn Carlson for performing the binding assays.

References and notes

- Adlercreutz, H.; Mousavi, Y.; Clark, J.; Hockerstedt, K.; Hamalainen, E.; Wahala, K.; Makela, T.; Hase, T. *J. Steroid. Biochem. Mol. Biol.* **1992**, *41*, 331.
- Lamartiniere, C. A. *Am. J. Clin. Nutr.* **2000**, *71*, 1705S.
- Ju, Y. H.; Doerge, D. R.; Allred, K. F.; Allred, C. D.; Helferich, W. G. *Cancer Res.* **2002**, *62*, 2474.
- Morito, K.; Hirose, T.; Kinjo, J.; Hirakawa, T.; Okawa, M.; Nohara, T.; Ogawa, S.; Inoue, S.; Muramatsu, M.; Masamune, Y. *Biol. Pharm. Bull.* **2001**, *24*, 351.
- Setchell, K. D.; Brown, N. M.; Lydeking-Olsen, E. *J. Nutr.* **2002**, *132*, 3577.
- Chang, Y.-C.; Nair, M. G. *J. Nat. Prod.* **1995**, *58*, 1892.
- Marrian, G. F.; Haslewood, G. A. D. *Biochem. J.* **1932**, *26*, 1227.
- Shutt, D. A.; Braden, A. W. H. *Aust. J. Agric. Res.* **1968**, *19*, 545.
- Axelsson, M.; Kirk, D. N.; Farrant, R. D.; Cooley, G.; Lawson, A. M.; Setchell, K. D. *Biochem. J.* **1982**, *201*, 353.
- Rowland, I. R.; Wiseman, H.; Sanders, T. A.; Adlercreutz, H.; Bowey, E. A. *Nutr. Cancer* **2000**, *36*, 27.
- Xu, X.; Harris, K. S.; Wang, H. J.; Murphy, P. A.; Hendrich, S. *J. Nutr.* **1995**, *125*, 2307.
- Lampe, J. W.; Karr, S. C.; Hutchins, A. M.; Slavin, J. L. *Proc. Soc. Exp. Biol. Med.* **1998**, *217*, 335.

13. Setchell, K. D.; Brown, N. M.; Desai, P.; Zimmer-Nechemias, L.; Wolfe, B. E.; Brashear, W. T.; Kirschner, A. S.; Cassidy, A.; Heubi, J. E. *J. Nutr.* **2001**, *131*, 1362S.
14. Shutt, D. A.; Cox, R. I. *J. Endocr.* **1972**, *52*, 299.
15. Schmitt, E.; Dekant, W.; Stopper, H. *Toxicol. In Vitro* **2001**, *15*, 433.
16. Pettersson, K.; Gustafsson, J. Å. *Annu. Rev. Physiol.* **2001**, *63*, 165.
17. Wessely, F.; Prillinger, F. *Berichte* **1939**, *72B*, 629.
18. Lamberton, J. A.; Soares, H.; Watson, K. G. *Australian J. Chem.* **1978**, *31*, 455.
19. Ram, S.; Ehrenkauser, R. E. *Synthesis* **1988**, 91.
20. Ram, S.; Spicer, L. D. *Tetrahedron Lett.* **1988**, *29*, 3741.
21. Wahala, K.; Hase, T. A. *Heterocycles* **1989**, *28*, 183.
22. Pearlman, W. M. *Tetrahedron Lett.* **1967**, 1663.
23. Node, M.; Nishide, K.; Fujii, K.; Fujita, E. *J. Org. Chem.* **1980**, *45*, 4275.
24. Yunnikova, L. P.; Tigina, O. V. *Zhurnal Organicheskoi Khimii* **1993**, *29*, 651.
25. Srikrishna, A.; Reddy, T. J.; Viswajanani, R. *Tetrahedron* **1996**, *52*, 1631.
26. Verbit, L.; Clark-Lewis, J. W. *Tetrahedron* **1968**, *24*, 5519.
27. Kurosawa, K.; Ollis, W. D.; Redman, B. T.; Sutherland, I. O. *Chem. Commun. (London)* **1968**, *20*, 1265.
28. Carlson, K. E.; Choi, I.; Gee, A.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. *Biochemistry* **1997**, *36*, 14897.
29. Pike, A. C.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A. G.; Engstrom, O.; Ljunggren, J.; Gustafsson, J. Å.; Carlquist, M. *EMBO J.* **1999**, *18*, 4608.
30. Sun, J.; Meyers, M. J.; Fink, B. E.; Rajendran, R.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. *Endocrinology* **1999**, *140*, 800.
31. Kuiper, G. G.; Lemmen, J. G.; Carlsson, B.; Corton, J. C.; Safe, S. H.; van der Saag, P. T.; van der Burg, B.; Gustafsson, J. Å. *Endocrinology* **1998**, *139*, 4252.
32. Mazur, W. *Baillieres Clin. Endocrinol. Metab.* **1998**, *12*, 729.
33. Horn-Ross, P. L.; Lee, M.; John, E. M.; Koo, J. *Cancer Causes Control* **2000**, *11*, 299.
34. Tham, D. M.; Gardner, C. D.; Haskell, W. L. *J. Clin. Endocrinol. Metab.* **1998**, *83*, 2223.
35. Chang, Y. C.; Nair, M. G. *J. Nat. Prod.* **1995**, *58*, 1892.
36. Chang, Y. C.; Nair, M. G.; Nitiss, J. L. *J. Nat. Prod.* **1995**, *58*, 1901.
37. Hawksworth, G.; Drasar, B. S.; Hill, M. J. *J. Med. Microbiol.* **1971**, *4*, 451.
38. Xu, X.; Duncan, A. M.; Merz, B. E.; Kurzer, M. S. *Cancer Epidemiol. Biomarkers Prev.* **1998**, *7*, 1101.
39. Rowland, I.; Faughnan, M.; Hoey, L.; Wahala, K.; Williamson, G.; Cassidy, A. *Br. J. Nutr.* **2003**, *89* (Suppl. 1), 838.
40. Setchell, K. D.; Borriello, S. P.; Hulme, P.; Kirk, D. N.; Axelson, M. *Am. J. Clin. Nutr.* **1984**, *40*, 569.
41. Sathyamoorthy, N.; Wang, T. T. *Eur. J. Cancer* **1997**, *33*, 2384.
42. Lampe, J. W. *J. Nutr.* **2003**, *133* (Suppl. 3.), 956S.
43. Duncan, A. M.; Merz-DemLow, B. E.; Xu, X.; Phipps, W. R.; Kurzer, M. S. *Cancer Epidemiol. Biomarkers Prev.* **2000**, *9*, 581.
44. Ingram, D.; Sanders, K.; Kolybaba, M.; Lopez, D. *Lancet* **1997**, *350*, 990.
45. Lin, X.; Huebner, V. *Curr. Opin. Drug Disc.* **2000**, *3*, 383.
46. Sun, J.; Baudry, J.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. *Mol. Endocrinol.* **2003**, *17*, 247.
47. Meyers, M. J.; Sun, J.; Carlson, K. E.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. *J. Med. Chem.* **1999**, *42*, 2456.
48. Meyers, M. J.; Sun, J.; Carlson, K. E.; Marriner, G. A.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. *J. Med. Chem.* **2001**, *44*, 4230.
49. Stauffer, S. R.; Coletta, C. J.; Tedesco, R.; Sun, J.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. *J. Med. Chem.* **2000**, *43*, 4934.
50. Kuiper, G. G. J. M.; Carlsson, B.; Grandien, K.; Enmark, E.; Häggblad, J.; Nilsson, S.; Gustafsson, J. Å. *Endocrinology* **1997**, *138*, 863.
51. Versteeg, M.; Bezuidenhoudt, B. C. B.; Ferreira, D. *Tetrahedron* **1999**, *55*, 3365.
52. Katzenellenbogen, J. A.; O'Malley, B. W.; Katzenellenbogen, B. S. *Mol. Endocrinol.* **1996**, *10*, 119.
53. McKenna, N. J.; O'Malley, B. W. *J. Steroid Biochem. Mol. Biol.* **2000**, *74*, 351.
54. McKenna, N. J.; O'Malley, B. W. *Endocrinology* **2002**, *143*, 2461.
55. McKenna, N. J.; O'Malley, B. W. *Cell* **2002**, *108*, 465.
56. Committee on Toxicity: Phytoestrogens and Health *The Food Standards Agency*; Aviation House: London, 2003; pp 154–164.
57. Fang, H.; Tong, W.; Shi, L. M.; Blair, R.; Perkins, R.; Branham, W.; Hass, B. S.; Xie, Q.; Dial, S. L.; Moland, C. L.; Sheehan, D. M. *Chem. Res. Toxicol.* **2001**, *14*, 280.
58. Kuiper, G. G.; Enmark, E.; Peltö-Huikko, M.; Nilsson, S.; Gustafsson, J. Å. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 5925.
59. Mosselman, S.; Polman, J.; Dijkema, R. *FEBS Lett.* **1996**, *392*, 49.
60. Couse, J. F.; Korach, K. S. *Endocr. Rev.* **1999**, *20*, 358.
61. Couse, J. F.; Curtis Hewitt, S.; Korach, K. S. *J. Steroid Biochem. Mol. Biol.* **2000**, *74*, 287.
62. Harris, H. A.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. *Endocrinology* **2002**, *143*, 4172.
63. Lindberg, M. K.; Moverare, S.; Skrtic, S.; Gao, H.; Dahlman-Wright, K.; Gustafsson, J. Å.; Ohlsson, C. *Mol. Endocrinol.* **2003**, *17*, 203.
64. Jensen, E. V.; Cheng, G.; Palmieri, C.; Saji, S.; Makela, S.; Van Noorden, S.; Wahlstrom, T.; Warner, M.; Coombes, R. C.; Gustafsson, J. Å. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 15197.
65. Palmieri, C.; Cheng, G. J.; Saji, S.; Zelada-Hedman, M.; Warri, A.; Weihua, Z.; Van Noorden, S.; Wahlstrom, T.; Coombes, R. C.; Warner, M.; Gustafsson, J. Å. *Endocr. Relat. Cancer* **2002**, *9*, 1.
66. Prins, G. S.; Birch, L.; Couse, J. F.; Choi, I.; Katzenellenbogen, B.; Korach, K. S. *Cancer Res.* **2001**, *61*, 6089.
67. Dudley, K. H.; Miller, H. W.; Corley, R. C.; Wall, M. E. *J. Org. Chem.* **1967**, *32*, 2317.
68. Twaddle, N. C.; Churchwell, M. I.; Doerge, D. R. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* **2002**, *777*, 139.
69. Katzenellenbogen, J. A.; Johnson, H. J., Jr.; Myers, H. N. *Biochemistry* **1973**, *12*, 4085.